<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792593</url>
  </required_header>
  <id_info>
    <org_study_id>Senl-h19 CAR-T for B-ALL</org_study_id>
    <nct_id>NCT04792593</nct_id>
  </id_info>
  <brief_title>Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Senlang Biotechnology Inc., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Senlang Biotechnology Inc., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open, dose-escalating clinical study, taking patients with relapsed or&#xD;
      refractory acute lymphoblastic leukemia as the test subjects, including mouse-derived CAR-T&#xD;
      treatment failure or relapse, or for any reason cannot bridge the transplant r/r B-ALL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main research objectives:&#xD;
&#xD;
      To evaluate the safety and efficacy of Senl-h19 CAR-T in patients with relapsed or refractory&#xD;
      acute lymphoblastic leukemia Secondary research purpose To investigate the cytokinetic&#xD;
      characteristics of Senl-h19 CAR-T in patients with relapsed or refractory acute lymphoblastic&#xD;
      leukemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2020</start_date>
  <completion_date type="Anticipated">February 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence and severity of adverse events</measure>
    <time_frame>First 1 month post CAR-T cells infusion</time_frame>
    <description>To evaluate the possible adverse events occurred within first one month after CD7 CAR-T infusion, including the incidence and severity of symptoms such as cytokine release syndrome and neurotoxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Remission Rate</measure>
    <time_frame>3 months post CAR-T cells infusion</time_frame>
    <description>Remission Rate including complete remission(CR)、CR with incomplete blood count recovery(CRi)、No remission(NR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR)</measure>
    <time_frame>24 months post CAR-T cells infusion</time_frame>
    <description>duration of response (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>24 months post CAR-T cells infusion</time_frame>
    <description>progression-free survival (PFS) time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAR-T proliferation</measure>
    <time_frame>3 months post CAR-T cells infusion</time_frame>
    <description>the copy number of Senl h19 CAR- T cells in the genomes of PBMC by qPCR method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine release</measure>
    <time_frame>First 1 month post CAR-T cells infusion</time_frame>
    <description>Cytokine( IL-6,IL-10,IFN-γ,TNF-α ) concentration (pg/mL) by flow cytometry method</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>B-ALL</condition>
  <arm_group>
    <arm_group_label>Senl-h19 CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with Senl-h19 CAR-T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Senl-h19 CAR-T</intervention_name>
    <description>Biological: Senl-h19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis</description>
    <arm_group_label>Senl-h19 CAR-T</arm_group_label>
    <other_name>CD19 CAR-T</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Sign the informed consent and be willing and able to comply with the visit,&#xD;
             treatment protocol, laboratory examination, and other requirements of the study as&#xD;
             specified in the study procedure sheet; 2. A definite diagnosis of relapsed and&#xD;
             refractory acute B-lymphoblastic leukemia meets one of the following criteria: a)&#xD;
             Mouse CAR-T treatment fails or relapses; B) Unable to bridge the graft for any reason;&#xD;
             3. Eastern Cooperative Oncology Group (ECOG) score ≤2; 4. Age ≥2 years old, male or&#xD;
             female 5. CD19 positive tumor cells were detected by immunohistochemistry or flow&#xD;
             cytometry; 6. Expected survival longer than 3 months; 7. The collection time of&#xD;
             peripheral blood mononuclear immune cells must be at least 2 weeks from the last&#xD;
             radiotherapy or systematic treatment of patients;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Severe cardiac insufficiency; 2. Have a history of severe lung impairment; 3.&#xD;
             Complicated with other advanced malignant tumors; 4. Complicated with severe or&#xD;
             persistent infection that cannot be effectively controlled; 5. Complicated with severe&#xD;
             autoimmune diseases or congenital immune deficiency; 6. Active hepatitis (HBVDNA or&#xD;
             HCVRNA positive); Human immunodeficiency virus (HIV) infection or syphilis infection;&#xD;
             8. Have a history of severe allergy to biological products (including antibiotics); 9.&#xD;
             The female patient is pregnant and lactating, or has a pregnancy plan within 12&#xD;
             months; 10. Conditions that the investigator believes may increase the risk to the&#xD;
             subject or interfere with the outcome of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peihua MD Lu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Yanda Ludaopei Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peihua MD Lu, PhD</last_name>
    <phone>008618611636172</phone>
    <email>peihua_lu@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianqiang MD Li, PhD</last_name>
    <phone>008615511369555</phone>
    <email>limmune@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hebei yanda Ludaopei Hospital</name>
      <address>
        <city>Yanda</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peihua MD Lu, PhD</last_name>
      <phone>008618611636172</phone>
      <email>peihua_lu@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-ALL，h19，CAR-T</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

